Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Providers
Hospitals
Practices
Retail
Health Tech
AI and Machine Learning
Digital Health
Telehealth
Payers
Regulatory
Finance
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
DEI Awards
Innovation Awards
Resources
Webinars
Fierce Events
Industry Events
Podcasts
Survey
Whitepapers
Events
Subscribe
Subscribe
Providers
Hospitals
Practices
Retail
Health Tech
AI and Machine Learning
Digital Health
Telehealth
Payers
Regulatory
Finance
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
DEI Awards
Innovation Awards
Resources
Webinars
Fierce Events
Industry Events
Podcasts
Survey
Whitepapers
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Zepbound
Fierce Pharma
Novo, Lilly obesity meds 'highly cost-effective': ICER report
ICER has high confidence in the drugs' cost-effectiveness but also voiced concerns over the drugs' impact on healthcare budgets.
Eric Sagonowsky
Sep 9, 2025 10:30am
CVS hit with lawsuit over dropping Zepbound from formulary
Sep 5, 2025 4:58pm
CMMI eyes weight loss drug coverage as IVF pledge slips: reports
Aug 4, 2025 2:50pm
Payer Roundup—Setback in J&J case; Mental health parity lawsuit
Jan 31, 2025 3:00pm
Found introducing oral dissolvable GLP-1 tablet
Jan 8, 2025 9:00am
Ro, Eli Lilly strike deal to offer lower-price vials of Zepbound
Dec 12, 2024 8:00am